FarmaKeio, a Texas compounding pharmacy, made sterile drugs under insanitary conditions that put patients at risk.
What happened
FDA inspected the Richardson, Texas facility from March 1 to March 10, 2022, and found serious deficiencies in how the firm made drug products intended to be sterile. Investigators saw sterilization equipment unsuited for pharmaceutical use, inadequate disinfection when moving materials into cleaner areas, hazardous drugs handled without containment, failed airflow (smoke) studies, and media fills not run under worst-case conditions. The firm recalled its sterile products on April 5, 2022, and FDA found the firm's March 30, 2022 response lacked supporting documentation.
What FDA found
The firm used equipment for sterilization that was not appropriate for pharmaceutical use, and its testing of that equipment was inadequate, so it could not show the equipment worked throughout use.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Materials and supplies moved from the ISO 8 cleanroom into cleaner areas were not adequately disinfected.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Hazardous drug products were handled without adequate containment, separation, or cleaning of work surfaces and utensils, risking cross-contamination.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm did not run adequate smoke studies under working conditions to show that air flows in one direction in the ISO 5 area, so sterile products may be exposed to contamination.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Media fills (test runs using growth medium instead of drug) were not done under the most challenging conditions, so the firm has not shown it can make sterile products reliably.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm's environmental monitoring report set action levels that allowed microbial contamination in the ISO 5 area, which FDA treats as an insanitary condition.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
What FDA wants
FDA tells the firm to write back within 15 working days with the specific steps taken to fix each violation and documentation showing the fixes and how recurrence is prevented. FDA also strongly recommends a comprehensive assessment of aseptic operations, helped by a third-party consultant with sterile drug processing expertise.
Who should pay attention
- clinics and hospitals that buy compounded sterile injectables
- pharmacies and prescribers who refer patients to this compounder
- compounding pharmacies and contract manufacturers running aseptic operations
This is a summary. Read the original letter on fda.gov.